{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+and+Lymphoma+Malignancies&page=14", "query": { "condition": "Advanced Solid Tumor and Lymphoma Malignancies", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 336, "total_pages": 34, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+and+Lymphoma+Malignancies&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+and+Lymphoma+Malignancies&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T13:55:48.573Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04284774", "title": "Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Solid Neoplasm", "Recurrent Adrenal Gland Pheochromocytoma", "Recurrent Ectomesenchymoma", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Hepatoblastoma", "Recurrent Kidney Wilms Tumor", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Medulloblastoma", "Recurrent Melanoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdoid Tumor of the Kidney", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Recurrent Thyroid Gland Carcinoma", "Recurrent WHO Grade 2 Glioma", "Refractory Adrenal Gland Pheochromocytoma", "Refractory Ependymoma", "Refractory Ewing Sarcoma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Glioma", "Refractory Medulloblastoma", "Refractory Melanoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Rhabdoid Tumor", "Refractory Rhabdoid Tumor of the Kidney", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma", "Refractory Thyroid Gland Carcinoma", "Refractory WHO Grade 2 Glioma" ], "interventions": [ { "name": "Tipifarnib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 5, "start_date": "2020-10-13", "completion_date": "2027-09-30", "has_results": true, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-14T13:55:48.573Z", "location_count": 171, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04284774" }, { "nct_id": "NCT00004258", "title": "EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous/Nonmalignant Condition", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "cilengitide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "1999-12", "completion_date": "2001-09", "has_results": false, "last_update_posted_date": "2014-09-17", "last_synced_at": "2026-10-14T13:55:48.573Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004258" }, { "nct_id": "NCT01504490", "title": "Phase I Study of CS-7017 and Bexarotene", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "CS-7017 and Bexarotene", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2011-12", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2017-02-14", "last_synced_at": "2026-10-14T13:55:48.573Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01504490" }, { "nct_id": "NCT00003956", "title": "Combination Chemotherapy in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "lonafarnib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "1999-04", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2013-04-04", "last_synced_at": "2026-10-14T13:55:48.573Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003956" }, { "nct_id": "NCT01177397", "title": "Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma", "Diffuse Large B-Cell Lymphoma", "Glioblastoma Multiforme", "Hepatocellular Carcinoma", "Non-Small Cell Lung Cancer", "Neuroendocrine Tumors of Non-Pancreatic Origin", "Hormone Receptor-Positive Breast Cancer" ], "interventions": [ { "name": "CC-223", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2010-07-20", "completion_date": "2016-12-09", "has_results": true, "last_update_posted_date": "2022-12-13", "last_synced_at": "2026-10-14T13:55:48.573Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01177397" }, { "nct_id": "NCT00019513", "title": "Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Esophageal Cancer", "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer", "Liver Cancer", "Lung Cancer", "Lymphoma", "Pancreatic Cancer", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "1998-08", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2012-03-23", "last_synced_at": "2026-10-14T13:55:48.573Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019513" }, { "nct_id": "NCT04439318", "title": "Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Hematopoietic and Lymphoid Cell Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Trametinib Dimethyl Sulfoxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2016-02-25", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-14T13:55:48.573Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439318" }, { "nct_id": "NCT01169584", "title": "Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Rhabdomyosarcoma", "Lymphoma", "Wilm's Tumor", "Ewing's Sarcoma" ], "interventions": [ { "name": "Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jennerex Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 6, "start_date": "2010-08", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2016-01-21", "last_synced_at": "2026-10-14T13:55:48.573Z", "location_count": 2, "location_summary": "Cincinnati, Ohio • Houston, Texas", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01169584" }, { "nct_id": "NCT03082209", "title": "A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Cancer", "Hematologic Malignancies" ], "interventions": [ { "name": "ABBV-621", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2017-03-20", "completion_date": "2022-01-21", "has_results": false, "last_update_posted_date": "2022-12-09", "last_synced_at": "2026-10-14T13:55:48.573Z", "location_count": 10, "location_summary": "New Haven, Connecticut • Chicago, Illinois • Harvey, Illinois + 6 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT03082209" }, { "nct_id": "NCT00045006", "title": "Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-07", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2013-05-30", "last_synced_at": "2026-10-14T13:55:48.573Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00045006" } ] }